RT Journal Article
SR Electronic
T1 The Rapid Assessment of Aggregated Wastewater Samples for Genomic Surveillance of SARS-CoV-2 on a City-Wide Scale
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.17.21262170
DO 10.1101/2021.08.17.21262170
A1 Rouchka, Eric C.
A1 Chariker, Julia L.
A1 Saurabh, Kumar
A1 Waigel, Sabine
A1 Zacharias, Wolfgang
A1 Zhang, Mei
A1 Talley, Daymond
A1 Santisteban, Ian
A1 Puccio, Madeline
A1 Moyer, Sarah
A1 Holm, Rochelle H.
A1 Yeager, Ray A.
A1 Sokoloski, Kevin
A1 Fuqua, Joshua
A1 Bhatnagar, Aruni
A1 Smith, Ted
YR 2021
UL http://medrxiv.org/content/early/2021/08/20/2021.08.17.21262170.abstract
AB Throughout the course of the ongoing SARS-CoV-2 pandemic there has been a need for approaches that enable rapid monitoring of public health using an unbiased and minimally invasive means. A major way this has been accomplished is through the regular assessment of wastewater samples by qRT-PCR to detect the prevalence of viral nucleic acid with respect to time and location. Further expansion of SARS-CoV-2 wastewater monitoring efforts to include the detection of variants of interest / concern through next-generation sequencing have enhanced the understanding of the SARS-CoV-2 outbreak. In this report we detail the results of a collaborative effort between public health and metropolitan wastewater management authorities and the University of Louisville to monitor the SARS-CoV-2 pandemic through the monitoring of aggregate wastewater samples over a period of 28 weeks. Our data indicates that wastewater monitoring of water quality treatment centers and smaller neighborhood-scale catchment areas is a viable means by which the prevalence and genetic variation of SARS-CoV-2 within a metropolitan community of approximately one million individuals may be monitored. Importantly, these efforts confirm that regional emergence and spread of variants of interest / concern may be detected as readily in aggregate wastewater samples as compared to the individual wastewater sheds.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was supported by funding from Louisville Metro Public Health and Wellness. Part of this work was performed with assistance of the UofL Genomics Facility, which was supported by NIH/NIGMS KY INBRE P20GM103436, the J.G. Brown Cancer Center, University of Louisville, and user fees.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The University of Louisville Institutional Review Board classified this project as Non-Human Subjects Research (NHSR) (reference #: 717950).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw sequence data is available in NCBI Sequence Read Archive under BioProject number PRJNA735936.